Financial News

Disappointing study results for ImmunoGen

ImmunoGen Inc. (Nasdaq: IMGN) announced that development partner Roche reported disappointing Phase III MARIANNE study results for three HER2-targeted regimens to treat HER2-positive metastatic breast cancer. Shares of the biotechnology company plummeted $4.74 to close at $6.11.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback